Whole body hyperthermia in adjuvant therapy of children with renal cell carcinoma

被引:18
|
作者
Ismail-Zade, RS
Zhavrid, EA
Potapnev, MP
机构
[1] Belarusian Ctr Pediat Oncol & Haemotol, Minsk 223040, BELARUS
[2] Res Inst Oncol & Med Radiol, Minsk, BELARUS
关键词
doxorubicin; interferon-alpha; renal cell carcinoma; whole body hyperthermia;
D O I
10.1002/pbc.20299
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Whole body hyperthermia (WBH) in combination with chemotherapy has been proven to be effective in some patients with advanced malignancies. However, only limited experience exists regarding the application of WBH with chemotherapy in children. We present the results of applying WBH and chemotherapy in five children with advanced renal cell carcinoma (RCC). WBH (3 hr, 41.8-42.5 degrees C) combined with doxorubicin (50 mg/m(2)) and interferon-alpha (3 MU/m(2)) were applied to patients after nephrectomy and lymph node dissection. Each patient received three to eight courses of treatment three times weekly. All children tolerated the combined therapy well without complications. Follow-up of 7-68 months (median: 22 months) showed no tumor progression in patients with locoregional (n = 3) and metastatic (n = 2) disease. WBH with moderate dose doxorubicin and INF-alpha might be a feasible treatment option in childhood RCC. (c) 2005 Wiley-Liss, Inc.
引用
收藏
页码:679 / 681
页数:3
相关论文
共 50 条
  • [31] Whole body bone marrow MRI in renal cell carcinoma
    Steinborn, M
    Tiling, R
    Bruegel, M
    Oberneder, R
    Heuck, AF
    Reiser, MF
    [J]. RADIOLOGY, 2000, 217 : 355 - 355
  • [32] Adjuvant Therapy for Renal Cell Carcinoma: Past, Present, and Future
    Pal, Sumanta K.
    Haas, Naomi B.
    [J]. ONCOLOGIST, 2014, 19 (08): : 851 - 859
  • [33] Adjuvant therapy for renal cell carcinoma in 2023: hopes and disappointments
    Tsimafeyeu, Ilya
    Basin, Michael F. F.
    Bratslavsky, Gennady
    [J]. WORLD JOURNAL OF UROLOGY, 2023, 41 (07) : 1855 - 1859
  • [34] Patients perspectives on adjuvant therapy in renal cell carcinoma.
    Battle, Dena
    Jonasch, Eric
    Hammers, Hans J.
    Derweesh, Ithaar
    George, Daniel J.
    Bex, Axel
    Ljungberg, Borje
    Staehler, Michael D.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [35] Adjuvant therapy for renal cell carcinoma in 2023: hopes and disappointments
    Ilya Tsimafeyeu
    Michael F. Basin
    Gennady Bratslavsky
    [J]. World Journal of Urology, 2023, 41 : 1855 - 1859
  • [36] Adjuvant therapy for renal cell carcinoma, finally a new standard?
    Renner, Alex
    Rojas, Carlos
    Walton-Diaz, Annerleim
    Burotto, Mauricio
    [J]. FRONTIERS IN ONCOLOGY, 2022, 12
  • [37] Adjuvant therapy for renal-cell carcinoma: settled for now
    Duensing, Stefan
    Hohenfellner, Markus
    [J]. LANCET, 2016, 387 (10032): : 1973 - 1974
  • [38] Whole-body hyperthermia in the management of renal carcinoma patients with metastases in regional lymph nodes
    Krasny, SA
    Mavrichev, AS
    Zhavrid, EA
    Sukonko, OG
    Fradkin, SZ
    Polyakov, SL
    [J]. EXPERIMENTAL ONCOLOGY, 1998, 20 (01) : 66 - 70
  • [39] WHOLE-BODY HYPERTHERMIA AND LONIDAMINE AS ADJUVANT THERAPY TO TREATMENT WITH CISPLATIN WITH OR WITHOUT LOCAL RADIATION IN MOUSE BEARING THE LEWIS LUNG-CARCINOMA
    TEICHER, BA
    HOLDEN, SA
    ARA, G
    MENON, K
    [J]. INTERNATIONAL JOURNAL OF HYPERTHERMIA, 1995, 11 (05) : 637 - 645
  • [40] Clarification needed for pembrolizumab as adjuvant therapy in clear cell renal cell carcinoma
    Tarigopula, Vivek
    Nayak, Prasant
    Mandal, Swarnendu
    Das, Manoj Kumar
    Tripathy, Sambit
    [J]. LANCET ONCOLOGY, 2022, 23 (11): : 487 - 487